On 10th July 2017, NICE issued a new Technology Appraisal (TA) for bisphosphonates which links the recommendations for drug treatments to advice on fracture risk assessment outlined in their earlier guidance. The TA is not intended to provide treatment thresholds but offers recommendations on cost-effective use of bisphosphonates when using fracture risk assessment as described in their guideline www.nice.org.uk/
For the first time, these recommendations will apply to men as well as women.
The TA says that provided an individual meets the criteria for fracture risk assessment there should be no financial barrier to them receiving bisphosphonates if they have a fracture risk of at least 1% using FRAX or QFracture.…
Read more of this article
AMs in the National Assembly for Wales voted overwhelmingly in favour of a motion calling for a full multidisciplinary paediatric rheumatology service to be developed in Wales. Despite Cabinet Members abstaining, 27 AMs voted to support the motion, with nine abstentions and none against. There is now significant pressure on the government to take action.
By Chris Graham, Chief Executive, Picker Institute Europe

What a difference a month makes. When I last wrote an introduction to the ARMA newsletter we were in the run up to an election. I’m not sure anyone expected the result to go quite the way it did. Instead of increasing their majority the Government now has no majority at all and will have to rely on the support of other parties to get their plans through. What will this mean for people with MSK conditions?

National Voices
Guest blog by Liz Lingard, NHS RightCare Delivery Partner
Arthritis Research UK have created
